Researchers have been using RNA interference or soluble inhibitor to silence BCL6 to treat cancers in vitro or in an animal model, especially diffuse large B-cell lymphomas with aberrant BCL6 expression. Here, BCL6 is linked to diffuse large B-cell lymphoma.